FIELD: medicine.
SUBSTANCE: invention relates to a method of complex therapy of patients with viral diseases caused by SARS-CoV-2 pathogen. A method for the complex therapy of patients with viral diseases caused by SARS-CoV-2 pathogen is proposed, including the use of biologically active supplement after a severe form of infections, while the complex therapy includes the use of a probiotic supplement based on bifidobacteria, Biovestin of the strain Bifidobacterium longum MS-42, a dietary supplement in liquid form in a dose acceptable and sufficient depending on the age of the patient and the severity of the viral disease, Kudesan biologically active food supplement, the official medicinal product, Succinic acid the official medicinal product, while complex therapy is carried out for children who have had the specified viral disease in the form of children's multisystem inflammatory syndrome, the treatment course begins from the time the delayed effect of the disease is detected.
EFFECT: above method allows to reduce the severity of residual symptoms of COVID-19, which manifested itself in the form of a childhood multisystem inflammatory syndrome caused by SARS-CoV-2 virus, and remained after the completed basic course of treatment of patients.
7 cl, 3 dwg, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR COMPREHENSIVE REHABILITATION OF PATIENTS AFTER COVID-19 CORONAVIRUS INFECTION | 2021 |
|
RU2778774C1 |
METHOD OF TREATING CHILDREN SUFFERING FROM ROTAVIRUS INFECTION | 2014 |
|
RU2564899C2 |
METHOD FOR TREATMENT OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN ASSOCIATED WITH SARS-CoV-2 | 2021 |
|
RU2780939C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN ASSOCIATED WITH SARS-CoV-2 | 2023 |
|
RU2816437C1 |
METHOD OF TREATING COVID-19 IN CHILDREN AT RISK OF SEVERE CLINICAL COURSE OF DISEASE | 2023 |
|
RU2815303C1 |
METHOD FOR CORRECTING COGNITIVE IMPAIRMENT IN PATIENTS DURING THE PERIOD OF CONVALESCENCE OF CORONAVIRUS INFECTION CASED BY THE SARS-CoV-2 VIRUS | 2022 |
|
RU2801379C1 |
2-(IMIDAZOL-4-YL)-ETHANAMIDE OF PENTANEDIOIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING COVID-19 AND SYMPTOMS THEREOF | 2021 |
|
RU2824607C2 |
METHOD FOR PHYSICAL THERAPY OF ANOSMIA AFTER CORONAVIRUS INFECTION | 2021 |
|
RU2751823C1 |
METHOD FOR PREVENTIVE TREATMENT OF CORONAVIRUS INFECTION | 2020 |
|
RU2777462C2 |
METHOD FOR PREOPERATIVE PREPARATION OF PATIENTS WITH LUNG CANCER AFTER SUFFERING COVID-19 ASSOCIATED PNEUMONIA | 2021 |
|
RU2766291C1 |
Authors
Dates
2023-04-06—Published
2021-11-29—Filed